Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Keisaku Okada is active.

Publication


Featured researches published by Keisaku Okada.


Journal of Controlled Release | 2009

Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel.

Changxing Liu; Gang Zhao; Jian Liu; Nianchun Ma; Padmanabh Chivukula; Loren Perelman; Keisaku Okada; Zongyou Chen; David A. Gough; Lei Yu

BACKGROUND Targeting of a specific subset of cells is mandatory for the successful application of siRNA mediated silencing in anticancer therapy. A recent theory suggests that colon cancer is sustained by a small subpopulation of cells, termed cancer stem cells (CSCs). These cells are characterized by their innate drug resistance properties, which is one of the key factors of chemotherapy failure. The goal of this study was to assess whether a novel siRNA delivery carrier, with an appropriate siRNA, targeted to CD133+ cells has the potential to improve the efficacy of conventional chemotherapy. METHODS In this study, a novel synthetic siRNA carrier platform was designed and synthesized. This carrier was composed of a cationic oligomer (PEI(1200)), a hydrophilic polymer (polyethylene glycol) and a biodegradable lipid-based crosslinking moiety. Libraries of polymers were synthesized by varying their lipid composition. Their transfection efficacy was evaluated in vitro using CHOK1 cells. The polymer was characterized using molecular weight, particle encapsulation assay, particle size and surface charge analysis. RESULTS It was demonstrated that the lipid composition in the polymer plays a critical role in transfection. Optimizing the physicochemical properties of the polymers is crucial in achieving favorable knockdown. Lipid nano complex with composition PEI-Lipid(1:16) was the optimum ratio for gene silencing. Additionally, silencing of multidrug resistance gene (MDR1) and treatment with paclitaxel play a synergistic role in increasing the efficacy as compared to the drug alone. CONCLUSIONS In the present study a novel siRNA delivery carrier system with an MDR1-targeting siRNA (siMDR1) effectively reduced the expression of MDR1 in human colon CSCs (CD133+ enriched cell population), resulting in significantly increasing the chemosensitivity to paclitaxel.


Journal of Drug Targeting | 2007

A targeting approach for delivery of polymer microparticle-antibody conjugate against Vibrio parahaemolyticus-induced cytotoxicity to human intestinal epithelial cells

Feng Gao; Toshio Kodama; Xiuhao Chen; Keisaku Okada; Takeshi Honda

A major traditional of antibacterial drugs is antibiotic which promotes more rapid release of the toxins from bacteria cells in human body, which causes severe infection. The thermostable direct hemolysin (TDH) has been proposed as a major virulence factor of Vibrio parahaemolyticus (Vp). This study covers the preparation of polymer microparticle-antibody conjugate for the development of a drug targeting approach for antibacterial drug delivery. The chemical binding of antibodies (ab) to latex bead of 0.2 μm diameter was performed by using a water-soluble carbodiimide technique. Confocal microscopy revealed that the bacteria were strongly absorbed by the latex beads with bound anti-Vp polyclonal antibody (pAb). Treatment with a latex bead bound both anti-Vp pAb and anti-TDH monoclonal antibody (mAb) significantly inhibited bacterial adherence to the Caco-2 cells (p < 0.01), and reduced TDH-induced cytotoxicity in histology. These preliminary results suggest that it may be possible to effectively protect against Vp infection by using this microparticle-antibody conjugate delivery system.


Archive | 2005

Transepithelial delivery of peptides with incretin hormone activities

Chieko Kitaura; Kenjiro Minomi; Katsuyuki Okubo; Keisaku Okada; Natsuko Kagehisa; Masashi Kamiyama; Zheng Hou; Jian Liu; Yucheng Song; Lei Yu


Archive | 1999

Immunologic test method and immunologic test kit

Keisaku Okada; Takeshi Saika; Shuji Senda; Kenjiro Mori; Ken Sato


Archive | 2003

Antireflection film, optical element and display device

Tetsuo Inoue; Minoru Miyatake; Shinya Nakano; Keisaku Okada; Ryuichi Takamura; Kazuyoshi Tsuchimoto; 真也 中野; 徹雄 井上; 一喜 土本; 宮武 稔; 圭策 岡田; 竜一 高村


Archive | 2005

Aptamer capable of specifically adsorbing to bisphenol a and method for obtaining the aptamer

Keisaku Okada; Shuji Senda; Akio Kobayashi; Eiichiro Fukusaki; Itaru Yanagihara; Tsuyoshi Nakanishi


Archive | 1998

IMMUNOASSAY METHOD AND IMMUNOASSAY KIT

Keisaku Okada; Kenjiro Mori; Shuji Senda


Archive | 2011

LIGHT-EMITTING DEVICES FOR PHOTOTHERAPY

Sazzadur Rahman Khan; Amane Mochizuki; Sheng Li; David T. Sisk; Rajesh Mukherjee; Keisaku Okada


Archive | 2005

Aptamer capable of specifically adsorbing to Verotoxin-1 and method for obtaining the aptamer

Keisaku Okada; Shuji Senda; Akio Kobayashi; Eiichiro Fukusaki; Takeshi Honda; Itaru Yanagihara; Tsuyoshi Nakanishi


Archive | 2011

PHOTOTHERAPY METHODS AND DEVICES COMPRISING EMISSIVE ARYL-HETEROARYL COMPOUNDS

Amane Mochizuki; Sazzadur Rahman Khan; Sheng Li; Shijun Zheng; Jensen Cayas; Keisaku Okada; Brett T. Harding

Collaboration


Dive into the Keisaku Okada's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge